The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly.
Michael J. Overman
Research Funding - Roche
Binsah George
No relevant relationships to disclose
Karime Kalil
No relevant relationships to disclose
Renata Ferrarotto
No relevant relationships to disclose
Cathy Eng
No relevant relationships to disclose
Chris R. Garrett
No relevant relationships to disclose
Evelyn Loyer
No relevant relationships to disclose
Paulo Marcelo Hoff
No relevant relationships to disclose
Chusilp Charnsangavej
No relevant relationships to disclose
Scott Kopetz
Consultant or Advisory Role - Genentech (U)
Honoraria - Genentech